# Phase 1/2 Lymphoma, Mantle-Cell trials recruiting: 20 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials in phase 1/2 for Lymphoma, Mantle-Cell that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 Lymphoma, Mantle-Cell trials: 20 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/lymphoma-mantle-cell

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 20
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| August 26, 2026 | NCT07788118 | A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 1/2 | Recruiting | Relapsed/Refractory Large B-cell Lymphoma (LBCL), Diffuse Large B-Cell Lymphoma (DLBCL), Primary Mediastinal Large... | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07788118) |
| May 27, 2026 | NCT07609862 | A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies | Guangzhou Lupeng Pharmaceutical Company LTD. | Phase 1/2 | Recruiting | Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL), Waldenström... | 92 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07609862) |
| May 11, 2026 | NCT07578077 | Golcadomide in Combination With Rituximab for the Treatment of Patients With Relapsed or Refractory Mantle Cell Lymphoma | City of Hope Medical Center | Phase 1/2 | Recruiting | Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma | 58 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07578077) |
| November 20, 2024 | NCT06697184 | A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. | BeOne Medicines | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukemia, CLL, Mantle Cell Lymphoma, MCL | 258 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06697184) |
| August 21, 2024 | NCT06564038 | A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies | AstraZeneca | Phase 1/2 | Recruiting | Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma, B-cell... | 408 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06564038) |
| August 7, 2024 | NCT06542250 | A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell... | AstraZeneca | Phase 1/2 | Recruiting | B-cell Malignancies | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06542250) |
| August 1, 2024 | NCT06533579 | Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) | Vironexis Biotherapeutics Inc. | Phase 1/2 | Recruiting | B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma... | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06533579) |
| April 10, 2024 | NCT06357676 | Glofitamab Plus Ibrutinib With Obinutuzumab for the Treatment of Patients With Mantle Cell Lymphoma, IGNITE MCL Trial | OHSU Knight Cancer Institute | Phase 1/2 | Recruiting | Mantle Cell Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06357676) |
| September 21, 2023 | NCT06045910 | A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies | Cancer Research UK | Phase 1/2 | Recruiting | Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell, Lymphoma, Follicular, Lymphoma, B-Cell... | 84 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06045910) |
| September 8, 2023 | NCT06029309 | Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Mantle Cell Lymphoma | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06029309) |
| May 16, 2023 | NCT05861050 | Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma | City of Hope Medical Center | Phase 1/2 | Recruiting | Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05861050) |
| December 9, 2022 | NCT05643742 | A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies | CRISPR Therapeutics AG | Phase 1/2 | Recruiting | B-cell Lymphoma, Non-Hodgkin Lymphoma, B-cell Malignancy, Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma... | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05643742) |
| March 24, 2022 | NCT05294731 | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | BeOne Medicines | Phase 1/2 | Recruiting | B-cell Malignancy, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma... | 146 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05294731) |
| August 16, 2021 | NCT05006716 | A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | BeOne Medicines | Phase 1/2 | Recruiting | B-cell Malignancy, Marginal Zone Lymphoma, Follicular Lymphoma, Non-Hodgkin Lymphoma, Waldenström Macroglobulinemia... | 689 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05006716) |
| April 22, 2021 | NCT04855695 | Avo In R/R And Previously Untreated MCL | Sponsor not shown (see the record) | Phase 1/2 | Recruiting | Mantle Cell Lymphoma, Refractory Lymphoma | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04855695) |
| July 29, 2020 | NCT04491370 | Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma | New York Medical College | Phase 1/2 | Recruiting | B-cell Lymphoma, Burkitt Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal... | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04491370) |
| April 1, 2020 | NCT04329728 | The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | AVM Biotechnology Inc | Phase 1/2 | Recruiting | Lymphoid Malignancies | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04329728) |
| December 4, 2019 | NCT04186520 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | Medical College of Wisconsin | Phase 1/2 | Recruiting | Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma... | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04186520) |
| September 18, 2018 | NCT03676504 | Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR | University Hospital Heidelberg | Phase 1/2 | Recruiting | Acute Lymphoblastic Leukemia, Adult, Acute Lymphoblastic Leukemia, Pediatric, Chronic Lymphocytic Leukemia, Diffuse... | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03676504) |
| May 14, 2018 | NCT03523975 | Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma | City of Hope Medical Center | Phase 1/2 | Recruiting | Mantle Cell Lymphoma | 28 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03523975) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [BeOne Medicines](https://specstream.ai/data/clinical-trials/company/beone-medicines) | 3 |
| City of Hope Medical Center | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 2 |
| OHSU Knight Cancer Institute | 1 |
| Vironexis Biotherapeutics Inc. | 1 |
| CRISPR Therapeutics AG | 1 |
| New York Medical College | 1 |
| University Hospital Heidelberg | 1 |
| AVM Biotechnology Inc | 1 |
| Guangzhou Lupeng Pharmaceutical Company LTD. | 1 |
| Cancer Research UK | 1 |
| Medical College of Wisconsin | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 15 |
| China | 7 |
| Australia | 5 |
| Germany | 4 |
| France | 4 |
| United Kingdom | 4 |
| Italy | 3 |
| Japan | 3 |
| Spain | 3 |
| Denmark | 2 |
| South Korea | 2 |
| Brazil | 2 |
| Canada | 2 |
| Czechia | 1 |
| Taiwan | 1 |
| Georgia | 1 |
| Moldova | 1 |
| Sweden | 1 |
| Turkey (Türkiye) | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Fastener suppliers in the United States](https://specstream.ai/data/businesses/fastener-suppliers/united-states)
- [Financial services firms in the United States](https://specstream.ai/data/businesses/financial-services-firms/united-states)
- [Flight schools in the United States](https://specstream.ai/data/businesses/flight-schools/united-states)
- [Food and beverage exporters in the United States](https://specstream.ai/data/businesses/food-and-beverage-exporters/united-states)
- [French restaurants in the United States](https://specstream.ai/data/businesses/french-restaurants/united-states)
- [Gastropubs in the United States](https://specstream.ai/data/businesses/gastropubs/united-states)
